IQVIA Holdings Inc. IQV SPXR3KPHARMA

Q: What is the current share price of IQVIA Holdings Inc. (IQV)?

As of 2026-09-07 16:24 PDT, IQVIA Holdings Inc. (IQV) trades at $267.77 on NYSE. Its 52-week range is $156.66 to $271.62.

Q: What is the market capitalisation of IQV?

IQVIA Holdings Inc. (IQV) has a market capitalisation of $44.07B on NYSE.

Q: What is the P/E ratio of IQV?

IQV trades at a trailing price-to-earnings (P/E) ratio of 33.30. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.37.

Q: What is the return on equity (ROE) of IQV?

IQV has a return on equity (ROE) of 22.82%. Its return on capital employed (ROCE) is 10.10%.

Q: Is IQV a good stock to buy?

This page provides a data-driven analysis of IQVIA Holdings Inc. (IQV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.iqvia.com

Company Profile ↓

$267.77

+40.76% 1Y

Mkt Cap$44.07B

P/E33.30

P/B6.37

52W High$271.62

52W Low$156.66

Book Value$37.49

EPS (TTM)$8.04

Company Overview

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 22.8%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 13.1% per year over the last five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $16.31B (+5.9% YoY); net profit $1.36B.
Trailing 12 Months Year-on-year growth — revenue +8.7%, earnings -0.6%.
5-Year Trend Long-term compounding — revenue CAGR 9.9%, profit CAGR 13.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	9.94%
1 Year:	8.70%

Compounded Profit Growth

5 Years:	13.13%
1 Year:	-0.60%

Stock Price Performance

1 Year:	+40.76%
6 Months:	+53.46%
3 Months:	+45.96%
1 Month:	+15.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 97% of range

$156.66 $271.62

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)69.63 · Neutral

Price Performance

1M+15.20%

3M+45.96%

6M+53.46%

1Y+40.76%

Valuation vs Sector

P/E of 33.30 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 22.8%.
Profit CAGR of 13.1% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

33.30

Industry PE

25.17

Forward P/E

18.54

PEG Ratio

0.95

Book Value

$37.49

Price to Book

6.37

P/S

2.31

EV/EBITDA

17.58

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

9.94%

Profit 5Y

13.13%

Revenue (YoY)

8.70%

Earnings (YoY)

-0.60%

Profitability & Returns

ROCE

10.10%

ROE

22.82%

ROA

5.06%

Profit Margin

8.10%

Op Margin

13.03%

Gross Margin

32.97%

EPS (Latest Qtr)

$1.61

EPS (TTM)

$8.04

Balance Sheet & Liquidity

Debt/Equity

2.58

Quick Ratio

0.62

Current Ratio

0.71

Debt

$16.25B

Total Assets

$29.68B

Current Assets

$6.25B

Working Capital

$-2.09B

Ownership

Promoter Holding

1.09%

Chg in Prom Hold

-0.00%

FII / Inst Holding

103.41%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$44.07B

Total Revenue (TTM)

$16.98B

EBITDA

$3.05B

Free Cash Flow

$2.15B

Operating Cash Flow

$2.82B

Shares Outstanding

164.60M

Gross Margin

32.97%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IQV IQVIA Holdings Inc. SPXR3KPHARMA	267.77	33.30	$44.07B	0.00%	10.10%	22.82%	9.94%	13.13%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	2.36B	2.35B	2.47B	2.52B	2.56B	2.57B	2.59B	2.69B	2.68B	2.74B	2.77B	2.90B	2.75B	2.52B	2.79B	3.30B	3.41B	3.44B	3.39B	3.57B	3.54B	3.56B	3.65B	3.73B	3.74B	3.74B	3.81B	3.90B	3.83B	4.02B	4.10B	4.15B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	562.00M	563.00M	-	547.00M	449.00M	600.00M	-	731.00M	715.00M	727.00M	799.00M	795.00M	812.00M	802.00M	850.00M	862.00M	827.00M	863.00M	915.00M	-	-	-	-
Operating Income	143.00M	159.00M	166.00M	178.00M	179.00M	151.00M	168.00M	144.00M	202.00M	126.00M	195.00M	142.00M	183.00M	170.00M	181.00M	207.00M	210.00M	197.00M	204.00M	166.00M	193.00M	62.00M	187.00M	289.00M	342.00M	286.00M	302.00M	495.00M	453.00M	472.00M	471.00M	524.00M	481.00M	506.00M	520.00M	550.00M	496.00M	506.00M	553.00M	514.00M
Net Income	87.00M	85.00M	110.00M	105.00M	107.00M	87.00M	99.00M	-178.00M	100.00M	62.00M	88.00M	1.03B	69.00M	61.00M	60.00M	69.00M	58.00M	60.00M	57.00M	16.00M	82.00M	-23.00M	101.00M	119.00M	212.00M	175.00M	261.00M	325.00M	256.00M	283.00M	289.00M	297.00M	303.00M	288.00M	363.00M	285.00M	249.00M	266.00M	331.00M	274.00M
Diluted EPS	0.68	0.67	0.89	0.85	0.88	0.71	0.82	-0.74	0.43	0.28	0.40	4.79	0.32	0.29	0.29	0.34	0.29	0.30	0.29	0.09	0.42	-0.12	0.52	0.61	1.09	0.90	1.34	1.68	1.34	1.49	1.53	1.59	1.63	1.56	1.97	1.55	1.40	1.54	1.93	1.61

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	4.33B	4.87B	5.10B	5.46B	5.74B	6.82B	9.70B	10.41B	11.09B	11.36B	13.87B	14.41B	14.98B	15.40B	16.31B
Operating Income	345.25M	396.44M	462.33M	590.00M	646.00M	576.00M	665.00M	741.00M	777.00M	731.00M	1.39B	1.80B	1.98B	2.20B	2.18B
Net Income	241.77M	177.55M	226.59M	357.00M	387.00M	72.00M	1.28B	259.00M	191.00M	279.00M	966.00M	1.09B	1.36B	1.37B	1.36B
Diluted EPS	2.05	1.51	1.77	2.72	3.08	0.47	5.74	1.24	0.96	1.43	4.95	5.72	7.29	7.49	7.84
R&D Expense	9.99M	10.43M	4.96M	5.79M	3.34M	-	-	-	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	2.32B	2.50B	3.05B	3.30B	3.93B	21.21B	22.86B	22.55B	23.25B	24.56B	-	25.34B	26.68B	26.90B	29.94B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	4.98B	5.60B	5.83B	6.25B
Cash & Equivalents	646.62M	516.30M	567.73M	777.00M	867.00M	977.00M	1.20B	959.00M	891.00M	837.00M	1.81B	-	1.22B	1.38B	1.70B	1.98B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	1.33B	1.47B	1.39B	1.67B
Total Liabilities	-	-	3.86B	3.73B	4.00B	4.26B	12.35B	14.61B	15.60B	16.99B	18.28B	-	19.57B	20.57B	20.83B	23.31B
Current Liabilities	-	-	1.31B	1.48B	1.47B	1.59B	2.71B	3.16B	3.53B	3.94B	4.56B	-	5.58B	6.49B	6.96B	8.34B
Long Term Debt	-	-	2.37B	2.04B	2.28B	2.42B	7.11B	10.12B	10.91B	11.54B	12.38B	-	12.60B	12.96B	12.84B	13.88B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	12.44B	13.01B	13.90B	14.16B	-
Total Equity	-900.36M	-969.60M	-1.36B	-667.41M	-704.06M	-564.00M	8.63B	8.00B	6.71B	6.00B	6.00B	-	5.76B	6.11B	6.07B	6.50B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	256.40M	257.20M	258.20M	259.10M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	860.00M	970.00M	1.25B	1.42B	1.96B	2.94B	2.26B	2.15B	2.72B	2.65B
Investing Cash Flow	-	-	-	-	-	1.73B	-1.19B	-810.00M	-1.19B	-796.00M	-2.10B	-2.01B	-1.60B	-1.44B	-2.31B
Financing Cash Flow	-	-	-	-	-	-2.28B	-72.00M	-452.00M	-276.00M	-217.00M	-1.24B	-329.00M	-382.00M	-878.00M	-150.00M
Share Buybacks	14.32M	13.36M	6.43M	415.00M	515.00M	1.10B	2.62B	1.41B	949.00M	447.00M	406.00M	1.17B	992.00M	1.35B	1.24B

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	8.0%	8.1%	9.1%	10.8%	11.3%	8.5%	6.9%	7.1%	7.0%	6.4%	10.0%	12.5%	13.2%	14.3%	13.4%
Net Margin %	5.6%	3.6%	4.4%	6.5%	6.7%	1.1%	13.2%	2.5%	1.7%	2.5%	7.0%	7.6%	9.1%	8.9%	8.3%
ROE %	-24.9%	-13.1%	-34.0%	-50.7%	-68.6%	0.8%	16.0%	3.9%	3.2%	4.6%	-	18.9%	22.2%	22.6%	20.9%
ROCE %	-	33.3%	29.4%	32.3%	27.7%	3.1%	3.4%	3.9%	4.0%	3.7%	-	9.1%	9.8%	11.0%	10.1%

Shareholding Pattern

Insiders

1.09%

Institutions

103.41%

Public Float

104.54%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.84%	14.55M	$3.81B
2	Harris Associates L.P.	7.40%	12.18M	$3.19B
3	Vanguard Capital Management LLC	6.63%	10.91M	$2.85B
4	State Street Corporation	4.56%	7.51M	$1.97B
5	Vanguard Portfolio Management LLC	4.56%	7.50M	$1.96B
6	JPMORGAN CHASE & CO	3.73%	6.14M	$1.61B
7	Artisan Partners Limited Partnership	2.88%	4.74M	$1.24B
8	Boston Partners	2.71%	4.47M	$1.17B
9	Geode Capital Management, LLC	2.71%	4.45M	$1.17B
10	Invesco Ltd.	1.99%	3.28M	$857.27M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IQV

Google News Fri, 04 Sep 2026

IQV Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE5xSHJwYUIxcnJNOGV2eEs2MjZlVjQybkc4eHAzSmFHS3lWMDJ5ZktaU3dGUE5GYmZiemJUMUdHNlFzNGVpOTBMUG1sWF9XRDA?oc=5" target="_blank">IQV Stock Quote Price and Forecast</a>  <font colo…

Google News Mon, 07 Sep 2026

IQVIA Holdings, Inc. (IQV) Stock Analysis: Strong Analyst Consensus with 3.18% Potential Upside - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPRF9iaTBLNm8tWF9aRlBZLUs2T2UzUld2TDIwRDR1TkEzOWgxS1otXzZhcDlYMmtiOEhkeDMtX0RwSlAxZmlZQnlhWVE0SFVpUy1Ld0JEZjU2REdRY3Zrd2tyTjRzd0FrS1hmQml1eVl3OENmSDlhR01lcnYtajFYRmd2M0hQNnRDV2lUYW…

Google News Wed, 12 Aug 2026

IQV Stock Gains 42% in 3 Months: Here's What You Should Know - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPUDM2VFhHNWpwWXZpSnp1VXhWUkNlYzdrTXU1QnlqWDZNS1ZqbU9IWWdUV09wSmFkZGI2d2U0eHdSalVOSUpaclc3eGlGX1VMbU1HLUtiVEZhQi1IVTUzc0NVc2xGcjhMOWR5aFllbGw1Yk9mTTFoMllzZVBrWkRXZkNQTk9Vd3ItRFhkeE…

Google News Fri, 04 Sep 2026

IQVIA Holdings (NYSE: IQV) executive sells and transfers over 5,300 shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQRkd5d2NvT1kyTjNPRUFKRkNjY244MjRUUzJBdi1kWmJKbWR5YmI0MDJGdl9aSm52OHEwa1BtUUhMalZISGUyWm9Oci1ubXVOVWt4RXBWWjZHYlNEbDZDcERja2Z3OHo2Szh5NWlqdzF3Ui1uS3lzcElCXzlDZk1nRUMtUmNCZDBDMHYtQj…

Google News Sun, 06 Sep 2026

IQVIA’s New Predictive Clinical Development Platform Might Change The Case For Investing In IQVIA (IQV) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNdlJKakZJZlhZME9ZM2lSRzY4WHM3eDY5b2tfSmRxQTZrd0QyVW9hdUpERXYyRlhBT2pqNF9zekpjR28xbFJqNnpqSm5kSlNyOGxxTHZmcE4tLUE2bkg1eGlMZ2FCWFhsd3F0ajB0cVlSVlJlR1hIcUJCbzEySXZhcWpoeUdoOGg0YUpoem…

Google News hu, 03 Sep 2026

1 Profitable Stock with Solid Fundamentals and 2 That Underwhelm - StockStory

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZDRXcDVGTDNYRWZua3huUHR4MTM4TEt6ZW9GYi1yYnFyZ2dMZS0zZklkTlZYeVlvRTZ3ZGZBYWpHbmM4Sy1XMkNnck9hVFl5TzM3aWl0LWg1TGRaRFV0ZS1aaEI0VXY2WGdRX0c0bGh4ZGhBM0M4eWVlakxzLUNuSlF4UzJiWEVvRXhKT1…

IQV — Frequently Asked Questions

What is the current share price of IQVIA Holdings Inc. (IQV)?

As of 2026-09-07 16:24 PDT, IQVIA Holdings Inc. (IQV) trades at $267.77 on NYSE. Its 52-week range is $156.66 to $271.62.

What is the market capitalisation of IQV?

IQVIA Holdings Inc. (IQV) has a market capitalisation of $44.07B on NYSE.

What is the P/E ratio of IQV?

IQV trades at a trailing price-to-earnings (P/E) ratio of 33.30. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.37.

What is the return on equity (ROE) of IQV?

IQV has a return on equity (ROE) of 22.82%. Its return on capital employed (ROCE) is 10.10%.

Is IQV a good stock to buy?

This page provides a data-driven analysis of IQVIA Holdings Inc. (IQV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

IQVIA Holdings Inc. IQV SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

IQV Stock Quote Price and Forecast - CNN

IQVIA Holdings, Inc. (IQV) Stock Analysis: Strong Analyst Consensus with 3.18% Potential Upside - DirectorsTalk Interviews

IQV Stock Gains 42% in 3 Months: Here's What You Should Know - Yahoo Finance

IQVIA Holdings (NYSE: IQV) executive sells and transfers over 5,300 shares - Stock Titan

IQVIA’s New Predictive Clinical Development Platform Might Change The Case For Investing In IQVIA (IQV) - simplywall.st

1 Profitable Stock with Solid Fundamentals and 2 That Underwhelm - StockStory

IQV — Frequently Asked Questions

What is the current share price of IQVIA Holdings Inc. (IQV)?

What is the market capitalisation of IQV?

What is the P/E ratio of IQV?

What is the return on equity (ROE) of IQV?

Is IQV a good stock to buy?

Explore More